LOS ANGELES, Mar 19, 2007 -- Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia, reports its sales force now exceeds 200 associates nationwide, doubling once over the number reported mid-January, and again over the count in December 2006.

This amount exceeds the target of 175 the company had forecasted for the end of the first quarter ending March 30, 2007. It comprises the company's sales associates currently detailing products, those in training, and those scheduled to receive training over the next five weeks.

"This major milestone demonstrates Auriga's ability to attract sales associates at a faster rate than anticipated," notes Philip S. Pesin, Auriga's CEO. "As other pharmaceutical companies continue to reduce or eliminate dedicated sales teams due to high fixed costs and uncertain results, Auriga continues to expand."

For Auriga, the success of this strategy has also appeared in real market numbers. The company recently reported its total dispensed prescriptions reached a record 26,004 in January 2007, an increase of 324% from 6,141 in January 2006 (according to independently generated IMS data).

Added Pesin, "We continued to build momentum, fueled by an expanding strong portfolio of products, like the recently announced Zinx(TM) and Aquoral(TM), and have also established important distribution relationships and incentives. Altogether we have provided our sales force with a well-diversified product portfolio in a relatively short period of time. Now that our nine-month recruiting push is behind us, we will be able to focus on execution of our sales strategies, continued training and retention."

Auriga plans to add approximately 75 additional associates during the second half of 2007.

About Auriga Laboratories(TM)

Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The company's high-growth business model combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which is designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral(TM) for the treatment of xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), Extendryl(R), and Levall(R) families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the company's ability to secure additional financing, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's ability to find and execute strategic transactions, its potential exposure to litigation, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.

Auriga Laboratories, Inc.

Andrew D. Shales,

Chief Operating Officer,

678-282-1613

Fax: 678-282-1683

ashales@aurigalabs.com

or

Liolios Group, Inc.

Investor Relations:

Ron Both or Geoffrey Plank,

949-574-3860

ron@liolios.com